---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-016725"
form_type: "8-K"
ticker: "XXII"
cik: "0001347858"
company_name: "22nd Century Group, Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:07:53.688041+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# 22nd Century Q3 revenue up 148% to $19.4M; net loss $13.1M, VLN expansion to 12-18 states

## Summary
- Net revenue $19.4M (+148% YoY); tobacco $11.5M (+47.7%), hemp/cannabis $7.8M (new).
- Operating loss widened to $15.3M from $7.6M; net loss $13.1M ($0.06/share).
- VLN cigarette launch expands to CO, AZ, NM, UT; targeting 12-18 states within 12 months.
- Full quarter of GVB Biopharma revenue included; GVB passed NSF audit, pursuing pharma-grade certifications.
- Cash and investments $43.7M; manufacturing capacity +25%; largest VLN tobacco crop planted.

## SEC filing metadata
- accession: 0001558370-22-016725
- form_type: 8-K
- ticker: XXII
- cik: 0001347858
- company_name: 22nd Century Group, Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347858/000155837022016725/0001558370-22-016725-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347858/000155837022016725/xxii-20221108x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-016725
- JSON: https://secwatch.observer/filing/0001558370-22-016725.json
- Plain text: https://secwatch.observer/filing/0001558370-22-016725.txt

## Key facts
- Earnings Releases
  22nd Century Group, Inc. reported the third quarter ended September 30, 2022 results: revenue $19.4 Million.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $19.4 Million
  - Result: reported results
  source text: and Illinois, Launching in Four Corners States to Capture Market Share and Volume ● GVB Biopharma Acquisition Growing Revenue on Increased Volumes ● Third Quarter Net Sales $19.4 Million, Up 148% from the Third Quarter 2021 ● Strong Balance Sheet to Support Strategic Initiatives Including Accelerated VLN ® Expansion ​ BUFFALO, N.Y., November 8, 2022 (Globe
  evidence_url: https://www.sec.gov/Archives/edgar/data/1347858/000155837022016725/0001558370-22-016725-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.